Replimune Group Inc (REPL): Next-Year EPS Estimate 41.10%
As of 2026-11-12, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 41.10%. Featured in 6 EPS revision reports, most recently on 2026-11-06.
On 2026-10-30, analyst consensus for REPL's next-year EPS growth shifted from 41.11% to 41.10% — a negative change of 0.01 percentage points. The revised estimate has been sustained across 12 subsequent trading sessions. Current-year growth is projected at 31.74%.
What's Driving This
REPL’s
Generated 2026-10-30 from news as of 2026-10-30
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 41.10%
- EPS growth this year
- 31.74%
- EPS next quarter (est)
- -$0.58
- Last price
- $21.98
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 41.10% | 31.74% | -$0.58 | $21.98 |
| 2026-11-11 | 41.10% | 31.74% | -$0.58 | $21.78 |
| 2026-11-10 | 41.10% | 31.74% | -$0.58 | $23.28 |
| 2026-11-09 | 41.10% | 31.74% | -$0.58 | $22.26 |
| 2026-11-07 | 41.10% | 31.74% | -$0.58 | $21.62 |
| 2026-11-06 | 41.10% | 31.74% | -$0.58 | $21.62 |
| 2026-11-05 | 41.10% | 31.74% | -$0.58 | $20.02 |
| 2026-11-04 | 41.10% | 31.74% | -$0.58 | $20.69 |
| 2026-11-03 | 41.10% | 31.74% | -$0.58 | $20.65 |
| 2026-11-02 | 41.10% | 31.74% | -$0.58 | $19.49 |
| 2026-10-31 | 41.10% | 31.74% | -$0.58 | $17.61 |
| 2026-10-30 | 41.10% | 31.74% | -$0.58 | $17.61 |
| 2026-10-29 | 41.11% | 31.76% | -$0.58 | $17.39 |
| 2026-10-28 | 35.29% | 20.36% | -$0.73 | $16.06 |
| 2026-10-27 | 33.89% | 14.60% | -$0.78 | $13.05 |
| 2026-10-26 | 33.89% | 14.60% | -$0.78 | $12.47 |
| 2026-10-23 | 33.89% | 14.60% | -$0.78 | $11.46 |
| 2026-10-22 | 33.89% | 14.60% | -$0.78 | $11.99 |
| 2026-10-21 | 33.89% | 14.60% | -$0.78 | $11.72 |
| 2026-10-20 | 33.89% | 14.60% | -$0.78 | $11.42 |
| 2026-10-19 | 33.89% | 14.60% | -$0.78 | $11.05 |
| 2026-10-16 | 33.89% | 14.60% | -$0.78 | $10.86 |
| 2026-10-15 | 33.89% | 14.60% | -$0.78 | $11.75 |
| 2026-10-14 | 33.89% | 14.60% | -$0.78 | $11.39 |
| 2026-10-13 | 33.89% | 14.60% | -$0.78 | $12.11 |
| 2026-10-12 | 33.89% | 14.60% | -$0.78 | $13.07 |
| 2026-10-11 | 33.89% | 14.60% | -$0.78 | $13.42 |
| 2026-10-10 | 33.89% | 14.60% | -$0.78 | $13.42 |
| 2026-10-09 | 33.89% | 14.60% | -$0.78 | $13.42 |
| 2026-10-08 | 33.89% | 14.60% | -$0.78 | $13.04 |
Reports Featuring REPL
- 2026-11-06
NMRA, REPL Lead Healthcare Surge: EPS Revisions Fuel 20%+ Gains
- 2026-11-05
U Leads 23.5% EPS Revision Rally; REPL, BUR, CSGP Also Surge
- 2026-11-04
NMRA Jumps 46% as EPS Revisions Fuel Biotech Rally; REPL, BUR Follow
- 2026-11-03
NMRA Jumps 46% as Healthcare Small Caps Lead EPS Revision Rally
- 2026-11-02
Healthcare Micro-Caps Lead: COSM +34.8%, NMRA +28.2%, GMAB +25.4% on EPS Revisions
- 2026-04-22
FGI Surges 100% as EPS Revisions Spark Rally in 5 Stocks
Recent News
- Replimune Beats On A Shrinking Loss, But The TUDRIQEV Launch Is Still Measured In Accounts, Not RevenueEarnings Whispers
- Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate UpdateGlobeNewswire
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Replimune Group Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 41.10%, based on analyst consensus.
When was the latest EPS estimate revision for REPL?▾
The most recent revision occurred on 2026-10-30, when analysts adjusted the next-year EPS growth estimate from 41.11% to 41.10%.
What sector and industry does Replimune Group Inc belong to?▾
Replimune Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. REPL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.